By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    bowl of vegetable salad
    Raw Foods: benefits and harms
    November 9, 2021
    pros and cons of the keto diet
    Read This Before You Follow the Keto Diet
    May 18, 2022
    spinal cord injuries
    4 Potential Causes of Spinal Cord Injuries (and How to Seek Compensation)
    May 25, 2022
    Latest News
    7 Most Common Healthcare Accreditation Programs: Which Should You Use?
    August 20, 2025
    Hospital Pest Control and the Fight Against Superbugs
    August 20, 2025
    Hygiene Beyond The Clinic: Attention To Overlooked Non-Clinical Spaces
    August 13, 2025
    5 Steps to a Promising Career as a Healthcare Administrator
    August 3, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    TBI: Some Surprising Statistics
    February 9, 2016
    Your Keys to Safer, Even More Secure Healthcare Cloud Services
    January 13, 2015
    4 Career Options in Healthcare Industry that Combine Big Data & Healthcare
    February 5, 2021
    Latest News
    How Social Security Disability Shapes Access to Care and Everyday Health
    August 22, 2025
    How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
    August 22, 2025
    How One Fall Can Lead to a Long Road of Medical Complications
    August 22, 2025
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Lawyers and Medical Decision-Making
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Lawyers and Medical Decision-Making
Business

Lawyers and Medical Decision-Making

gooznews
gooznews
Share
4 Min Read
SHARE

We’ve heard a lot over the years about the inappropriate role of lawyers in the medical system. The complaints usually center  on trial lawyers who sue physicians for malpractice and drug companies for failure to warn consumers about unsafe drugs and devices. We’ve heard much less about lawyers who work for drug companies and try to game the regulatory system.

We’ve heard a lot over the years about the inappropriate role of lawyers in the medical system. The complaints usually center  on trial lawyers who sue physicians for malpractice and drug companies for failure to warn consumers about unsafe drugs and devices. We’ve heard much less about lawyers who work for drug companies and try to game the regulatory system.

This latter problem was in full display this afternoon at the FDA hearing on Roche/Genentech’s appeal of the FDA’s decision to remove breast cancer from Avastin’s label.  Paul Schmidt, a Covington & Burling attorney representing Genentech, repeatedly tried to pin down FDA oncology drugs chief Richard Pazdur and his colleagues as to whether they had ever specified that replicating the progression free survival benefit seen in the first trial that led to accelerated approval would satisfy the FDA and therefore lead to permanent approval.

Pazdur repeatedly replied that progression free survival was a surrogate marker of benefit and had to be accompanied by some other benefit, such as improved quality of life. Of course, a trial showing extended survival would be the best. But given the adverse events profile of Avastin — increased cardiovascular deaths; GI perforations; an increase in hypertension in a quarter of patients — any increase in time before a tumor began progressing as the sole benefit would have to be substantial before a drug would be approved based on that surrogate marker alone.

More Read

Physician Marketing, Medical Practice Marketing, Targeted Local Marketing
Grow Your Medical Practice’s Patient Volume by Marketing to New Movers
11 Crucial Hospital Management Tips
The Importance of Physician Engagement in Value-Based Initiatives
Debt Ridden Hospital in the UK Taken Over By Private Firm
EHR’s a Money Loser (Or is It?)

“The approval process is not about a median progression free survival,” Pazur said. “It’s about a risk benefit analysis. The magnitude of a progression free survival change has to be viewed in the context of the safety profile of the drug, the disease setting, the existing therapies, and patient performance status. For me to give you an exact progression free survival would be impossible to do.”

Schmidt pressed ahead: “Did CDER say to Genentech that .8 months progression free survival (the amount seen in one of the follow-up trials) wouldn’t be enough to support approval?”

“I don’t believe we ever said that,” Pazdur said. “All we’re asking for here is one trial that shows clinical benefit.”

There has only been one new piece of clinical evidence introduced at this hearing. A phase II trial published in Lancet Oncology in April, where Avastin was added to several chemotherapy regimens, showed it slightly increased the time before the cancer resumes progressing by a few months — again! — and had no impact on the long-term mortality rate for women struck by a recurrence of this devastating disease.

So, there have been five follow-up trials, and not one has replicated the initial evidence that led to accelerated approval. Tomorrow, Genentech and its lawyers get to present their side of the story. If the company attempts to present new evidence, it will violate the ground rules set by the FDA for the hearing (not to mention normal legal procedures). Why do I think the real purpose of this hearing is to lay the groundwork for a lawsuit against the FDA?

TAGGED:AvastinFDAGenentechhealthcare businesshealthcare law
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

engineer fitting prosthetic arm
How Social Security Disability Shapes Access to Care and Everyday Health
Health care
August 20, 2025
a woman explaining the document
How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
Public Health
August 20, 2025
physiotherapist at work
How One Fall Can Lead to a Long Road of Medical Complications
Health care
August 20, 2025
Common Healthcare Accreditation Programs
7 Most Common Healthcare Accreditation Programs: Which Should You Use?
Health News
August 20, 2025

You Might also Like

Q and A: Addressing an Enormous Public Health Problem with a Simple Technology Solution

January 15, 2014

States Should Stop Diverting Stop-Smoking Money

May 27, 2012
health start-up
BusinessTechnology

Health Start-Ups! – Fearless Teen Scientists Finding Better Ways To Detect Cancer

May 28, 2013
Business

6 Important Questions to Ask Your Medical Courier

February 22, 2022
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?